anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE:To obtain activated water promoting functions in a living body by introducing water from which impurities have been removed in a water purifying tank into an electrolytic treatment device to electrolyze the same and introducing produced alkaline ion water into an activating ceramic part to which a substance promoting functions in a living body is added to activate the same to take out activated water. CONSTITUTION:The purified water formed in a water purifying part is introduced into an electrolytic treatment device 1 through an alkaline water passage 513 and an acidic water passage 514. An anion in water is attracted to an anode in the alkaline water passage 513 and moved to the water of the acidic water passage 514 to raise the concn. of the anion to obtain acidic ion water. The cation in the water of the acidic water passage 514 is attracted to a cathode to raise the concn. of the alkali ion in the water of the alkaline water passage to form alkaline ion water 63. This alkaline ion water 63 is introduced into an activating ceramic part 2 packed with a ceramic base material 21 to which a substance promoting functions in a living body is added to be activated to be taken out as activated water 65.
Subjects received 3 primary doses of Synflorix at 2, 4 and 6 months of age co-administered with Infanrix-hexa and booster dose of Synflorix at 15-18 months of age co-administered with Infanrix-IPV/Hib. All vaccines were administered intramuscularly in the right (Synflorix) or the left (Infanrix-hexa, Infanrix-IPV/Hib) thigh (primary dose) or deltoid (booster dose).
<P>PROBLEM TO BE SOLVED: To provide a method for accumulating a partial peptide of a mite antigenic protein comprising a plurality of T-cell epitopes or a mite antigenic peptide modified such that a conformation for being recognized as an antigen is not formed in rice seeds and to provide a plant in which the peptide is accumulated.  <P>SOLUTION: The preparation of rice seeds (rice) in which a modified mite antigenic peptide is accumulated is attempted in order to solve the problem. As a result thereof, transgenic rice in which the modified mite antigenic peptide is expressed and accumulated is developed. Immune tolerance is induced by allowing mice to orally ingest the transgenic rice. Thereby, effects thereof particularly on asthma are demonstrated to accomplish the achievement.  <P>COPYRIGHT: (C)2009,JPO&INPIT
The present invention relates to a freezing drying formulation of a microelement and a preparation method thereof. The formulation of the present invention is prepared by that a compound containing various microelements and a solution of excipient which is acceptable on pharmacy are froze and dried. The excipient is adacceptable on mannitol, glycine, lactose, sodium chloride, dextrose and (or) other pharmacy. The preparation method of the formulation of the present invention comprises: preparing various microelement compounds and the solution of the excipient which is acceptable on the pharmacy; filtering, sterilizing, freezing and drying the microelement compounds and the excipient solution. The formulation of the present invention has the advantages of easy storage and transportation, stabilisation for longtime placement, convenient use, etc. The preparation method of the present invention is simple and easy and is good for large-scale production.
I2-ART intervention will be modeled based on the Parent Empowerment Program model. It will use methods of adult learning, direct instruction to share knowledge or techniques for practice, group support, modeling, vicarious learning, and practice opportunities (i.e., role rehearsals). I2-ART training includes 40 hours of didactic and interactive sessions (10 sessions of 4 hours each) covering the following areas: 1) conceptual framework, 2) listening, engagement, and boundary-setting skills; 3) ADHD psychoeducation (e.g., diagnosis, treatment, shared decision-making tools), and 4) service options. The caregivers in the I2-ART group will receive the intervention for 3 months. The I2-ART will be implemented by the family navigators and will include a 2-hour face-to-face meeting, at least three monthly in-person meetings, and intermittent contact between in-person meetings by phone calls, texts or emails, as determined by the family navigator-caregiver dyad.
PROBLEM TO BE SOLVED: To obtain a new sulfur-containing heterocyclic compound having antifungal actions. SOLUTION: This compound is represented by formula I (R1 is a sulfur- containing heterocyclic ring which may have a halogen; R2 is a 1-4C alkyl; R3 is a hydrocarbon having >=6 π electrons), e.g. trans-N-(6,6-dimethyl-2-hepten-4- ynyl)-N-methyl-2-(3-chloro-3-thienyl)-2-thienyl)-2-propenylamine represented by formula II. The compound represented by formula I is obtained by carrying out the Wittig reaction of a compound represented by formula III with methyltriphenylphosphonium bromide and butyl-lithium. A compound group represented by formula IV, in which Cl is especially preferred as the halogen, is especially preferred in the compound represented by formula I.  When the above compound is used as an antifungal agent, the daily dose thereof for an adult is preferably 1-10,000 mg for, e.g. oral administration or parenteral injection and an adequate amount of a skin preparation for external use and a pessary containing 0.1-10 wt.% of the compound is preferably applied and administered.
Hyponatremia has been reported during treatment with SNRIs and SSRIs, including PROZAC. In many cases, this hyponatremia appears to be the result of the syndrome of inappropriate antidiuretic hormone secretion (SIADH). Cases with serum sodium lower than 110 mmol/L have been reported and appeared to be reversible when PROZAC was discontinued. Elderly patients may be at greater risk of developing hyponatremia with SNRIs and SSRIs. Also, patients taking diuretics or who are otherwise volume depleted may be at greater risk [see Use in Specific Populations (8.5)]. Discontinuation of PROZAC should be considered in patients with symptomatic hyponatremia and appropriate medical intervention should be instituted. 

Signs and symptoms of hyponatremia include headache, difficulty concentrating, memory impairment, confusion, weakness, and unsteadiness, which may lead to falls. More severe and/or acute cases have been associated with hallucination, syncope, seizure, coma, respiratory arrest, and death.
Morphine sulfate extended-release is intended for use in patients who require continuous, around-the-clock opioid analgesia for an extended period of time. As with any potent opioid, it is critical to adjust the dosing regimen for morphine sulfate extended-release for each patient, taking into account the patient's prior analgesic treatment experience. Although it is clearly impossible to enumerate every consideration that is important to the selection of the initial dose of morphine sulfate extended-release, attention should be given to the points underDOSAGE AND ADMINISTRATION. 

Opioid analgesics have a narrow therapeutic index in certain patient populations, especially when combined with CNS depressant drugs, and should be reserved for cases where the benefits of opioid analgesia outweigh the known risks of respiratory depression, altered mental state, and postural hypotension.

Selection of patients for treatment with morphine sulfate extended-release should be governed by the same principles that apply to the use of any potent opioid analgesics. Specifically, the increased risks associated with its use in the following populations should be considered: the elderly or debilitated and those with severe impairment of hepatic, pulmonary, or renal function; hypothyroidism; adrenocortical insufficiency (e.g., Addison's Disease); CNS depression or coma; toxic psychosis; prostatic hypertrophy, or urethral stricture; acute alcoholism; delirium tremens; kyphoscoliosis, or inability to swallow.

The administration of morphine sulfate extended-release may obscure the diagnosis or clinical course in patients with acute abdominal conditions. 

Morphine sulfate extended-release may aggravate pre-existing convulsions in patients with convulsive disorders.
A modified gelatine is prepared by heating a mixture of gelatine and either ascorbic acid, a mixture of ascorbic acid and citric acid or a mixture of citric acid and sorbose in the presence of sorbitol.  The term "ascorbic acid" includes iso-ascorbic acid.  Either type A or B gelatine having a bloom within the range 30-100 may be used.ALSO:Milk is fortified by the addition of vitamin beadlets comprising a fat-soluble vitamin-containing material, and in cases where said material is other than a -tocopherol, a -tocopherol, and a modified gelatin.  The latter is prepared by heating a mixture of gelatin and either ascorbic acid, a mixture of ascorbic acid and citric acid or a mixture of citric acid and sorbose in the presence of sorbitol.  The term "ascorbic acid" also includes iso-ascorbic acid.  The vitamin beadlets may optionally contain antioxidants e.g. butylated hydroxyanisole, butylated hydroxytoluene, platicizers e.g. sorbitol or corn syrup, buffers e.g. sodium citrate or colouring agents.  The vitamin-containing material may be any material which contains vitamins A, D, E or K e.g. vitamin A acetate or palmitate.  The vitamin beadlets may be initially dispersed in a liquid vehicle to form a concentrate which is subsequently added to the milk.ALSO:Vitamin compositions in beadlet form comprise a fat-soluble vitamin-containing material, and (incases where said material is other than a -tocopherol) a -tocopherol, and modified gelatin, optionally with antioxidants e.g. butylated hydroxyanisole, butylated hydroxytoluene, plasticisers e.g. sorbitol or corn syrup, buffers e.g. sodium citrate or colouring agents.  The modified gelatin is prepared by heating a mixture of gelatin and either ascorbic acid, a mixture of ascorbic acid and citric acid or a mixture of citric acid and sorbose in the presence of sorbitol.  The term "ascorbic acid" also includes iso-ascorbic acid.  In a preferred method of manufacturing the vitamin compositions, an oil phase consisting of the vitamin-containing material, or (in cases where said material is other than a -tocopherol) a mixture thereof with a -tocopherol and optionally an antioxidant is emulsified with an aqueous solution containing the modified gelatin.  The emulsion may be converted into beadlets by passing the emulsion through a revolving spray head and introducing the droplets into a suspension of collecting powder in air.  The collecting powder may be a free-flowing starch ester, resistant to water-wetting, known as "Dry-Flo". Specified fat-soluble vitamin-containing materials include vitamin A acetate and palmitate.
Agents which modulate pathways of apoptotic induction or repression in which products of opioid peptide precursor genes participate, are used as inducers of apoptosis in cells and in tumour cells in particular. Methods of treatment employing such agents and pharmaceutical compositions containing them are described. Examples of such agents include agents which interact with extracellular or cell surface membrane bound opioid-like molecules or their receptors. The agents may be coupled to peptides which assist in the transport of the agents through the cell membrane to promote internalisation and accumulation in the cell nucleus if this is the site at which the agent produces apoptosis. Screening methods and assays for such agents form a further aspect of the invention. Furthermore, the treatment of lens cells to prevent cell regrowth following cataract surgery by inducing apoptosis is described.
PURPOSE:The titled formulating ingredient, containing aldioxa and cimetidine as active constituents, in a specific proportion, capable of accelerating the cure of the ulcer, reducing the side effects, e.g. the counter coup of gastric acid and having great effects even in a small dose. CONSTITUTION:An antiulcer formulating ingredient containing aldioxa and cimetidine as active constituents at (1:3)-(4:1) weight ratio, preferably 3:1 weight ratio. The aldioxa (aluminum dihydroxyallantoinate) has the activity of accelerating the cure of the peptic ulcer, and the cimetidine (1-cyano-2-methyl-3-[2-{[(5- methyl-4-imidazolyl)methyl]thio}ethyl]guanidine) has the activity of suppressing the secretion of gastric acid and reducing the size of the ulcer. The above- mentioned active constituents are formulated with the well-known excipient or binder to give the aimed pharmaceutical. The dosage form is preferably for the oral administration.
The invention relates to application of liquiritin drug-loaded nanoparticles in preparation of a drug for treating psoriasis, belonging to the technical field of nano traditional Chinese medicines. The multicomponent medicine comprises baicalin, paeoniflorin, and liquiritin. Baicalin can regulate NF-kB and JAK/STAT signal pathways, inhibit skin inflammatory reaction, and improve atopic dermatitis lesion; it is also possible to reduce inflammation of the skin in psoriatic mice by inhibiting the IL-17/IL-23 axis. The paeoniflorin can regulate and control various signal paths, including GPCR (GPCR-mediated pathway), JAK2/STAT3 (JAK activator and activator of transcription) pathways and the like, can obviously reduce the transcription level of STAT3, and inhibit Th17 cells from secreting cytokines, thereby relieving the symptoms of psoriasis. The liquiritin is one of main effective components of liquorice, and has good treatment effect on acute lung injury, cancer and cell injury caused by inflammation. According to the invention, the liquiritin nanoparticles are used for loading the medicine, and the corresponding medicine-loading nanoparticles can be better absorbed by intestinal tract cells and inflammatory cells, and can exert a good psoriasis treatment effect.
Seroepidemiological characteristics of human papillomavirus (HPV) in community residents reflect natural infection and can guide the reform of vaccination programs. A population-based serological survey was conducted in Guangdong Province. Serum anti-HPV IgG antibody levels were determined by an ELISA. Neutralizing antibodies against HPV6, 11, 16, and 18 were detected via a pseudovirus-based neutralization assay (PBNA). A total of 5122 serum samples were collected from community residents, including 1989 males and 3133 females, in three cities of Guangdong Province. The rate of HPV IgG antibody positivity in females was 5.39% (95% CI: 4.6-6.2), which was greater than that in males (2.36%; 95% CI: 1.7-3.1). HPV IgG antibodies were more frequently detected in females aged 51-60 years (11.30%; 95% CI: 7.6-16.0), whereas in males, the detection increased with age and reached 4.94% (95% CI: 2.8-6.9) in the group aged ≥71 years. The seropositivity of neutralizing antibodies against HPV6 and 11 was greater than that against HPV16 and 18. The serum neutralizing antibody titers in individuals who received three doses of a vaccine were 7- to 12-fold greater than those in individuals who did not receive the vaccine. The neutralizing antibody titers slightly decreased within 40 months and ranged from 0.038 to 0.057 log ED50 per month. A moderate consistency between the HPV ELISA and PBNA results was observed (Kappa score = 0.49, r = 0.249, 0.635, 0.382, and 0.466 for HPV6, 11, 16, and 18, respectively). The HPV seropositivity rate among healthy residents of Guangdong Province was found to be low among children and adolescents and to increase with age. The serum neutralizing antibody titers were significantly greater in the vaccine group than that in the control group, and this difference persisted over time, which indicated promising protection against HPV infection.
Hair-styling lotion contg. reducing agent and an agent preventing excessive hair-curling comprises (a) 0.01-1 wt.% glyoxylic acid, (b) 0.01-1 wt.% ascorbic acid and (c) 0.1-2 wt.% dithiodiglycolate. The lotion contains no mercaptans or ceratin-softening substances and has a pH value of 3-6.5. Also claimed is the styling-treatment whereby the hair is firstly (a) put on curlers, then (b) put in curlers and after a period of time (c) rinsed with water and finally (d) arranged and dried by the hairdresser. USE/ADVANTAGE - The styling-treatment is suitable for all hair types, reduces the risk of excessive hair-curling and counters atmospheric oxidn. of both the lotion and hair, resulting in hair with a harmonised quality.
TAK-994 Dose A tablets, orally, on Days 1 and 2 of Treatment Period 1, followed by TAK-994 placebo-matching tablets, orally, on Days 1 and 2 of Treatment Period 2, further followed by TAK-994 Dose B tablets, orally, on Days 1 and 2 of Treatment Period 3. A Washout Period of at least 7 days will be maintained between each treatment period.
CARNEXIV may cause transient renal function impairment. Renal tubule cell vacuolization and degeneration were observed in animal studies in which carbamazepine was formulated with the solubilizing agent sulfobutylether beta-cyclodextrin sodium salt, an ingredient of CARNEXIV. In clinical studies with CARNEXIV, elevations of urinary N-acetyl-β-D-glucosaminidase (NAG), an early marker of renal tubular injury, were observed in about 40% of patients. These elevations resolved following CARNEXIV discontinuation. In addition, a patient with mild renal impairment prior to receiving CARNEXIV had a significant increase in serum creatinine (from 105 umol/L to 195 umol/L) during CARNEXIV treatment; creatinine partially returned to baseline values after CARNEXIV discontinuation. 

Renal function and electrolytes should be monitored during treatment with CARNEXIV [see Dosage and Administration (2.3)]. Patients with renal impairment may be at greater risk for an adverse effect of CARNEXIV on renal function, and should be closely monitored during CARNEXIV treatment. CARNEXIV should generally not be used in patients with moderate or severe renal impairment.

Use of CARNEXIV for periods of more than 7 days has not been studied.
PROBLEM TO BE SOLVED: To provide a remedy for nephritis and kidney debility, having a fundamental remedial effect. SOLUTION: This remedy for the nephritis and the kidney debility is prepared from Cypyinus Caypoil and Lycine Maxll. Amounts of the Cypyinus Caypoil and the Lycine Maxll contained in the remedy are, preferably, 86.96-88.89% and 11.11-13.04%, respectively. Active chemical ingredients in the remedy are absorbed by the gastrointestinal tract and circulate through the body of a patient, when the remedy is administered to the patient. The remedy has an antiinflammatory remedial effect on the kidney organ so as to rapidly develop its action within a short time (about 2 hr), moderates such a symptom that the kidney organ is indurated and contracted, and activates tissue cells of the kidney organ.  Further, the remedy enhances the vital activity of the kidney, quenches a pathologically aggravated syndrome including spread and extension of the kidney induration, recovers physiological function of the kidney organ, makes the kidney organ have normal physiological effects, and prevents adverse effects of the nephritis on the secretion function of the kidney.
In this study, the investigators seek to explore if patients who receive continuous IV vasoactive medication infusion have a difference in blood pressure (BP) response measured and reported continuously versus intermittently. Adult patients (age \> 18 years old) admitted to the Neuroscience Intensive Care Unit at The University of Texas Southwestern Medical Center with a neurological, neurosurgical, or neurovascular diagnosis are eligible. Patients must be receiving Intravenous vasoactive medication infusing at the time of consent. Eligible patients must have an indwelling Arterial line as placed as part of standard of care. There are no restrictions on obtaining Non-invasive BP during data collection. Patients, or legally authorized representatives (LARs), must be able to consent themselves in English. Subjects will be excluded if they are: Under the age of 18, pregnant, or they are currently incarcerated. Because the study does not have the availability to develop foreign language consents, subjects (or LARs) who are unable to read and communicate in English will also be excluded. The primary null hypothesis is that continuously acquired data from the arterial line have a similar mean and standard deviation as documented values in the EMR. The first step in examining this hypothesis is a simple paired T-test. An F-test will be used to compare the standard deviations. Rejection of the null will indicate the need for additional models to compare the median, Interquartile range (IQR), minimum and maximum values. The area under the curve will be determined as a function of the time above or below the prescribed BP range and the time spent outside of that range.
Two sessions a week for two weeks of: 25 minutes listening to audio book excerpts (with non mindfulness practice). Participants will be asked not to engage in formal mindfulness practice during the study.
Eligible patients randomized to this arm will be asked to answer questions regarding HIV risk using the Denver HIV Risk Score (DHRS), an empirically-developed clinical prediction instrument for assessing HIV risk, to identify patients at increased risk for HIV infection. Patients identified as being at increased risk for HIV infection will be offered rapid HIV testing. HIV testing will occur on a 24-hour basis as part of routine ED care.
MOT115816 will be conducted as a multi-center, randomized, double-blind, placebo controlled study to investigate the ability of the motilin receptor agonist GSK962040 to improve L-DOPA pharmacokinetics (PK) by enhancing gastric emptying via motilin receptor agonism. Subjects will be randomized to receive 50 mg GSK962040 or placebo in a 2:1 ratio administered orally once daily for 7-9 days. The study will consist of a screening/baseline period, a treatment period, and a 14-day post treatment safety follow-up visit. During this period participants will be asked to attend the study center for 5 visits 3 of which will last approximately 5 hours. The duration of each patient's participation in the study from screening to follow-up visit will be approximately 7-8 weeks. For three of the visits, subjects will visit the clinical unit fasted and prior to taking their first morning L-DOPA dose. Volunteers will undergo a complete physical (including cardiovascular monitoring (ECG), vital signs, blood samples, and medical history), measurement of plasma L-DOPA levels, completion of patient diary to capture the amount of awake time (in hours) spent "on" without dyskinesias, "on" with troublesome dyskinesias, "on" with non-troublesome dyskinesias, and "off" and gastric symptoms, non-motor and motor symptoms assessments (MDS-UPDRS rating scale and "finger taps") and measurement of gastric emptying rate.
Prior studies in humans indicate that while energy expenditure response is similar after consumption of equal amounts of fructose, glucose, and sucrose (a dimer of glucose + fructose), carbohydrate oxidation and blood glucose responses differ. Elevated carbohydrate oxidation responses appear to be driven by the presence of fructose, and elevated blood glucose responses appear to be driven by the presence of glucose. Prior work also suggests that post-ingestive signals of glucose availability, measure specifically as blood glucose levels, intestinal glucose transporter activity, and carbohydrate oxidation rate, are all associated with elevated brain response to calorie-predictive flavor cues and reward learning of these flavor cues. However, in animal models, glucose has been shown to repeatedly and reliably condition these calorie-predictive learning responses, but fructose does not. Human work has indicated that oxidation of glucose is critical for these responses. Thus, it is unclear what roles fructose and glucose each play in conditioning reward responses and flavor-calorie learning. We hypothesize that fructose plays a synergistic role in enhancing flavor-calorie learning without itself conditioning the reward response.